Drug discount management company Kalderos sent email messages to 340B hospitals this week once again announcing the launch of its 340B Pay service to let drug companies pay 340B ceiling prices as back-end rebates instead of as front-end discounts on drugs dispensed at contract pharmacies. The launch previously was scrubbed a handful of times.
Kalderos says 340B Pay will eliminate the risk of duplicate discounts and give manufacturers a way to address concerns about drug diversion. It released a report this week that found that its 340B rebate model improves covered entity cash flow relative to existing contract pharmacy replenishment models.
Drug discount management company Kalderos sent email messages to 340B hospitals this week once again announcing the launch of its 340B Pay service to let drug companies pay 340B ceiling prices as back-end rebates instead of as front-end discounts on drugs dispensed at contract pharmacies. The launch previously was scrubbed a handful of times.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
